According to the ministry, Gennova has developed an mRNA vaccine candidate (HGCO19) in collaboration with HDT Biotech Corporation, Seattle, USA. According to the ministry, the novel mRNA vaccine candidate, HGCO19, has all the necessary arsenal to guide the host cells to make the antigen spike protein of the virus, reported to interact with host cells … Continue reading Gennovo’s vaccine candidate, HGCO19 first human injection before 31 Dec 2020